Singapore markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
13.60+0.09 (+0.70%)
As of 10:52AM EDT. Market open.

Takeda Pharmaceutical Company Limited

1-1, Nihonbashi-Honcho 2-chome
Chuo-ku
Tokyo 103-8668
Japan
81 3 3278-2111
https://www.takeda.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees49,281

Key executives

NameTitlePayExercisedYear born
Mr. Christophe WeberPresident, CEO & Representative Director4.57MN/A1966
Dr. Seigo IzumoChair of Management BoardN/AN/AN/A
Mr. Milano FurutaCFO & DirectorN/AN/A1978
Mr. Haruhiko HirateMember of Management BoardN/AN/A1957
Mr. Salvatore Alesci M.D., Ph.D.Member of Management Board and Head of R&D Global Science & Biomedical PolicyN/AN/A1975
Norimasa TakedaChief Accounting Officer & Corporate ControllerN/AN/AN/A
Mr. Iwaaki TaniguchiSenior Vice President of Corporate Finance & Controlling DepartmentN/AN/AN/A
Mr. Gabriele RicciChief Data & Technology OfficerN/AN/A1978
Mr. Christopher David O'ReillyGlobal Head of Investor Relations & Global FinanceN/AN/AN/A
Mr. Yoshihiro NakagawaGlobal General CounselN/AN/A1960
Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Corporate governance

Takeda Pharmaceutical Company Limited’s ISS governance QualityScore as of 1 July 2024 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.